周新信必可治疗哮喘..pptVIP

* Patients were asked to state the length of time between initial signs or warnings and when symptoms start to become bothersome/between bothersome symptoms and when symptoms are at their worst/between symptoms at their worst and recovery. Base: All Respondents who noticed signs or warnings (n=1,596)/ all respondents (n=2,407) The mean period from the early signs to the peak symptoms of a worsening was 6 days. This gradual development has also been noted and evaluated in the FACET study1, where exacerbations were characterized by a gradual increase in symptoms over 5 to 7 days, followed by a more rapid increase over 2 to 3 days. 1 Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer C-A, OByrne PM, L?fdahl C-G, Pauwels RA, Ullman A. Exacerbations of asthma - a descriptive study of 425 severe exacerbations. American Journal of Respiratory and Critical Care Medicine 1999;160(2):594-9. * The introduction of fixed combination inhalers combining an ICS with a LABA has been a key development in asthma management. The combination product, Symbicort? Turbuhaler?, contains the ICS, budesonide, with the LABA, formoterol, in a single inhaler, thereby providing both anti-inflammatory and long-acting bronchodilatory medication. Symbicort SIT is a new, innovative treatment strategy to address the deficiencies of traditional asthma therapy, and satisfy the unmet needs of the many patients whose asthma remains suboptimally controlled. The underlying concept of Symbicort SIT is that patients receive a regular daily maintenance dose of Symbicort plus additional inhalations as needed for relief of symptoms. The corollary of the Symbicort SIT regimen is that, as patients take additional inhalations as needed, they will not only receive rapid-acting bronchodilator medication for symptom relief, but also additional anti-inflammatory therapy to control airway inflammation. Therefore, patients can use just one inhaler to control their asthma effectively, without the need for a s